Skip Navigation



Annals of Oncology Advance Access published online on June 21, 2006
Annals of Oncology, doi:10.1093/annonc/mdl132
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/9/1386    most recent
mdl132v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cazzaniga, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cazzaniga, M. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received March 12, 2006
Revised May 2, 2006
Accepted May 3, 2006

original article

Adjuvant systemic treatment of early breast cancer: the NORA study

M. E. Cazzaniga 1 *, G. Mustacchi 2, P. Pronzato 3, A. De Matteis 4, F. Di Costanzo 5, I. Floriani 6, and On behalf of the NORA Study Group

1 Medical Oncology, Treviglio Hospital, Treviglio
2 Medical Oncology, University of Trieste, Trieste
3 Medical Oncology, La Spezia Hospital, La Spezia
4 Medical Oncology, Pascale Institute, Napoli
5 Medical Oncology, Careggi Hospital, Firenze
6 Oncology Department, Istituto di Ricerche Farmacologiche ‘Mario Negri’, Milano, Italy

* To whom correspondence should be addressed.
M. E. Cazzaniga, E-mail: oncologia{at}tin.it


  Abstract

Background: Despite recommendations contained in international guidelines, factors such as the type of oncology centre, geographic distribution and the introduction of scientific advances into clinical practice can influence the choice of recommended treatment for early breast cancer. The NORA study is a prospective, longitudinal cohort study aimed at investigating tumour characteristics, treatment modalities, and other factors that influence therapeutic choices in early breast cancer patients who have undergone mastectomy or breast-conserving surgery (BCS).

Patients and methods: From January 2000 to early 2004, we collected data on methods of cancer diagnosis, type of surgery and adjuvant medical treatment administered to the first 10 consecutive patients treated in 2000-2002 and the first 20 consecutive patients in 2003 and 2004 at 71 oncology centres in Italy, with the approval of the ethical committee at each centre.

Results: Approximately one-quarter of the cases (26.5%) were detected through screening programmes. BCS was performed in 63.7% and sentinel node biopsy (SNB) occurred in 11.1% of the patients. Of the 3515 total cases, 56.5% were node-negative. Grade 2 cancers comprised 51.3%, and 66.2% were hormone-receptor positive (ER+/PgR+). Chemotherapy (CHT) followed by hormone therapy (HT) was the most prescribed treatment (48.5%). CHT was mainly anthracycline-based (52.9%) and most patients received tamoxifen alone (77.7%) or after CHT (85.2%). For node-negative patients, HR+ and menopause status are the factors influencing the choice to add HT after CHT; patients with HR+ and pT4 tumours are more likely to receive HT instead of CHT. In node-positive patients, the addition of HT is influenced by HR+ status, the opportunity to have HT instead of CHT, and menopause.

Conclusions: NORA is the first large cohort study to describe the factors that influence therapeutic choices in early breast cancer. Understanding these findings can help physicians in daily clinical practice.

Keywords: adjuvant therapy; breast cancer; cohort study.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
G. Mustacchi, M. Mansutti, C. Sacco, S. Barni, A. Farris, M. Cazzaniga, M. Cozzi, and C. Dellach
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study
Ann. Onc., April 1, 2009; 20(4): 655 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. Cazzaniga, P. Pronzato, G. Mustacchi, A. De Matteis, F. Di Costanzo, E. Rulli, and I. Floriani
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study
Ann. Onc., October 1, 2008; 19(10): 1811 - 1812.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study
Ann. Onc., December 1, 2007; 18(12): 1976 - 1980.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Mustacchi, M. Cazzaniga, P Pronzato, A De Matteis, F Di Costanzo, I Floriani, and On behalf of the NORA Study Group
Breast cancer in elderly women: a different reality? Results from the NORA study
Ann. Onc., June 1, 2007; 18(6): 991 - 996.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.